Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe SepsisSteven M. Opal, for the ACCESS Study Group, Derek C. Angus et al.|JAMA|2013Cited by 797
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial*Steven M. Opal, John P. Pribble, Pierre‐François Laterre et al.|Critical Care Medicine|2004Cited by 145
Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe SepsisSteven M. Opal, Daniel P. Rossignol, Derek C. Angus et al.|Unknown|2013Cited by 7